NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
Clinical Trials
10 trialsNCT00924066 2019-11-21
Ixabepilone to Treat Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00672009 2018-10-24
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Terminated
NCT00546364 2016-03-10
IXTEND
R-Pharm
Phase 2 Terminated
NCT01057212 2015-09-07
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Providence Health & Services
Phase 2 Terminated
NCT00022542 2015-04-15
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00079326 2014-06-02
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00023946 2014-05-14
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00033306 2013-08-05
BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
University of Alabama at Birmingham
Phase 2 Terminated
NCT00790894 2011-05-18
HIT
Hellenic Cooperative Oncology Group
Phase 2 Terminated